Celldex Therapeutics, Inc. (CLDX) Analysts See $-0.12 EPS

July 14, 2018 - By Nadine Davis

Analysts expect Celldex Therapeutics, Inc. (NASDAQ:CLDX) to report $-0.12 EPS on August, 14.They anticipate $0.11 EPS change or 47.83 % from last quarter’s $-0.23 EPS. After having $-0.19 EPS previously, Celldex Therapeutics, Inc.’s analysts see -36.84 % EPS growth. The stock increased 0.12% or $0.0006 during the last trading session, reaching $0.5206. About 1.26 million shares traded. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has declined 79.56% since July 14, 2017 and is downtrending. It has underperformed by 92.13% the S&P500.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage

Among 4 analysts covering Celldex Therapeutics (NASDAQ:CLDX), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Celldex Therapeutics had 4 analyst reports since March 8, 2018 according to SRatingsIntel. On Thursday, March 8 the stock rating was maintained by Jefferies with “Hold”. Leerink Swann maintained the shares of CLDX in report on Thursday, March 8 with “Market Perform” rating. The firm has “Neutral” rating given on Tuesday, April 17 by Cantor Fitzgerald. The company was downgraded on Monday, April 16 by Cowen & Co.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company has market cap of $74.65 million. The Company’s drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It currently has negative earnings. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers.

More recent Celldex Therapeutics, Inc. (NASDAQ:CLDX) news were published by: Seekingalpha.com which released: “Celldex Therapeutics Salvage Value” on June 15, 2018. Also Fool.com published the news titled: “Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics” on June 29, 2018. Nasdaq.com‘s news article titled: “How David Gardner’s Biggest Losers Demonstrate Why Long-Term Investing Wins” with publication date: July 02, 2018 was also an interesting one.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.